share_log

IRADIMED CORPORATION to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

IRADIMED CORPORATION to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

IRADIMED CORPORATION将在2025年1月15日参加第43届J.P.摩根医疗会议的演讲。
Quiver Quantitative ·  12/19 21:45

IRADIMED announces CEO and CFO will present at J.P. Morgan Healthcare Conference on January 15, 2025.

Quiver AI Summary

IRADIMED CORPORATION announced that CEO Roger Susi and CFO Jack Glenn will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. The company, a leader in MRI-compatible medical devices and the exclusive provider of a non-magnetic IV infusion pump system, offers innovative solutions designed for safe use during MRI procedures. Their MRidium MRI-compatible IV infusion pump and the 3880 monitoring system utilize non-magnetic features to ensure reliable fluid delivery and patient monitoring without interference from MRI machines. Interested parties can access the presentation via the company's investor website. The release also includes forward-looking statements regarding the company's plans and potential risks.

Potential Positives

  • IRADIMED CORPORATION is scheduled to present at the prestigious 43rd Annual J.P. Morgan Healthcare Conference, which elevates the company's visibility within the healthcare sector.
  • The company continues to highlight its unique position as the only provider of a non-magnetic intravenous infusion pump system, emphasizing its innovative edge in MRI-compatible medical devices.
  • The introduction of the Iradimed 3880 MRI-compatible patient vital signs monitoring system demonstrates the company's commitment to enhancing patient safety and monitoring during MRI procedures, addressing a critical need in medical care.
  • The ability of the Iradimed 3880 system to operate reliably in magnetic fields up to 30,000 gauss indicates the robustness and adaptability of the company's products in diverse clinical environments.

Potential Negatives

  • The press release heavily emphasizes forward-looking statements, indicating uncertainty about the company's future plans and performance, which may concern investors.
  • The mention of potential disruptions in the limited supply chain for products could signal vulnerabilities that might affect operations and financial stability.
  • Risks associated with receiving FDA clearance for new products could hinder product development and market expansion, posing a significant challenge for growth.

FAQ

What is the date of the J.P. Morgan Healthcare Conference presentation?

The presentation will take place on January 15, 2025, at 5:15 p.m. Pacific Time.

Where can I access the IRADIMED presentation?

You can access the live and archived webcast on the "Events and Presentations" section of the Company's investor website.

What products does IRADIMED specialize in?

IRADIMED specializes in MRI-compatible medical devices, including non-magnetic IV infusion pumps and patient vital signs monitoring systems.

What is unique about IRADIMED's IV infusion pump?

The IV infusion pump is specially designed to be non-magnetic, ensuring safety during MRI procedures.

How does the Iradimed 3880 system enhance patient safety?

The Iradimed 3880 system allows uninterrupted vital signs monitoring in MRI environments, increasing safety for critically ill patients.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.


$IRMD Insider Trading Activity

$IRMD insiders have traded $IRMD stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

Here's a breakdown of recent trading of $IRMD stock by insiders over the last 6 months:

  • JOHN GLENN (CHIEF FINANCIAL OFFICER) sold 2,500 shares.
  • ANTHONY VUOTO sold 2,690 shares.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$IRMD Hedge Fund Activity

We have seen 86 institutional investors add shares of $IRMD stock to their portfolio, and 60 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

  • RK CAPITAL MANAGEMENT, LLC removed 170,084 shares (-100.0%) from their portfolio in Q3 2024
  • BLACKROCK, INC. added 121,394 shares (+14.8%) to their portfolio in Q3 2024
  • SOLEUS CAPITAL MANAGEMENT, L.P. removed 102,067 shares (-100.0%) from their portfolio in Q3 2024
  • HILLSDALE INVESTMENT MANAGEMENT INC. removed 97,400 shares (-100.0%) from their portfolio in Q2 2024
  • GOLDMAN SACHS GROUP INC added 77,956 shares (+98.7%) to their portfolio in Q3 2024
  • TEACHER RETIREMENT SYSTEM OF TEXAS added 56,733 shares (+423.1%) to their portfolio in Q3 2024
  • ROUBAIX CAPITAL, LLC removed 50,307 shares (-100.0%) from their portfolio in Q2 2024

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Full Release



WINTER SPRINGS, Fla., Dec. 19, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging ("MRI") compatible medical devices and the only provider of a non-magnetic intravenous ("IV") infusion pump system announced today that Roger Susi, Chief Executive Officer and Jack Glenn, Chief Financial Officer, will present at the 43

rd

Annual J.P. Morgan Healthcare Conference.



The Company presentation will take place on Wednesday, January 15, 2025, at 5:15 p.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the "Events and Presentations" section of the Company's investor website at



.




About IRADIMED CORPORATION



IRADIMED CORPORATION is a leader in developing innovative Magnetic Resonance Imaging ("MRI") compatible medical devices. We design, manufacture, market, and distribute MRI-compatible medical devices, accessories, disposables, and related services.



We are the only known provider of a non-magnetic intravenous ("IV") infusion pump system specifically designed to be safe for use during MRI procedures. We were the first to develop an infusion delivery system that essentially eliminates many dangers and problems during MRI procedures. Standard infusion pumps contain magnetic and electronic components that can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium MRI compatible IV infusion pump system has a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts, and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe, and dependable fluid delivery before, during, and after an MRI scan, which is essential to critically ill patients who cannot be removed from their vital medications and children and infants who must generally be sedated to remain immobile during an MRI scan.



Our 3880 MRI-compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features to safely and accurately monitor a patient's vital signs during various MRI procedures. The Iradimed 3880 system operates dependably in magnetic fields up to 30,000 gauss, which means it can operate virtually anywhere in the MRI scanner room. The Iradimed 3880 has a compact, lightweight design, allowing it to travel with the patient from their critical care unit to the MRI and back, resulting in increased patient safety through uninterrupted vital signs monitoring and decreasing the amount of time critically ill patients are away from critical care units. The features of the Iradimed 3880 include wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo algorithms; non-magnetic respiratory CO2; invasive and non-invasive blood pressure; patient temperature, and optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The Iradimed 3880 MRI-compatible patient vital signs monitoring system has an easy-to-use design and effectively communicates patient vital signs information to clinicians.



For more information, please visit



.





Forward-Looking Statements




This release and any oral statements made regarding the subject of this release contain forward-looking statements as defined under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, that address activities that the Company assumes, plans, expects, believes, intends, projects, indicates, estimates, or anticipates (and other similar expressions) will, should, or may occur in the future are forward-looking statements, including statements relating financial guidance, future quarterly cash dividends, construction costs for the Company's new facility in Orlando, Florida, and the Company's strategic plans, objectives, and intentions. The forward-looking statements are based on management's current belief and currently available information on the outcome and timing of future events. The forward-looking statements involve risks and uncertainties, including, among others, that our business plans may change as circumstances warrant.



Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made, which reflect management's current estimates, projections, expectations, or beliefs, and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to; potential disruptions in our limited supply chain for our products; the Company's ability to receive U.S. Food and Drug Administration ("FDA") 510(k) clearance for new products and product candidates; unexpected costs, delays or diversion of management's attention associated with the design, manufacturing or sale of new products; the Company's ability to implement successful sales techniques for existing and future products and evaluate the effectiveness of its sales techniques; additional actions, warnings or requests from the FDA or other regulatory bodies; our significant reliance on a limited number of products; a reduction in international distribution; actions of the FDA or other regulatory bodies that could delay, limit or suspend product development, manufacturing or sales; the effect of recalls, patient adverse events or deaths on our business; difficulties or delays in the development, production, manufacturing and marketing of new or existing products and services; and changes in laws and regulations or in the interpretation or application of laws or regulations. Additional factors which could affect the forward-looking statements can be found in the Company's annual report on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K filed with the U.S. Securities and Exchange Commission (the "SEC") and available on the SEC's website at

http://www.sec.gov

. All forward-looking statements are based on information available to us on the date hereof, and we assume no obligation to update forward-looking statements.



Media Contact:
Jack Glenn
IRADIMED CORPORATION
(407) 677-8022


InvestorRelations@iradimed.com




声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发